Hepatitis C Drug Development and Drug-Drug Interaction Studies
The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV).
2011 TAG Update
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
President Obama’s Disappointing 2011 Budget Presents Sharp Gap Between Needs and Funds Available
By Coco Jervis and Sue Perez Negligible Increases for AIDS, TB, Viral Hepatitis Treatment and Research On Monday, February 1, 2010, President Barack Obama unveiled his fiscal year (FY) 2011 budget to the U.S. Congress. Global health programs were allocated…
Do the Right Thing: Eliminating Racial Disparities in Viral Hepatitis Drug Development
By Tracy Swan and Lei Chou Background: In the United States, the highest all-cause mortality rates are found among African American men and women aged 25 to 64. This racial disparity is underscored by a disproportionate burden of viral hepatitis…
2011 Pipeline Report
HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development Second Edition September 2011 Written by Polly Clayden, Simon Collins, Mark Harrington, Richard Jefferys, Tracy Swan, Javid Syed, and Claire Wingfield with a a contribution…
2011 Pipeline Report shows that medical prospects for people with HIV, hepatitis C, and tuberculosis have never been better
The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.
Letter to Secretary Clinton on the Global Fund to Fight AIDS, TB, and Malaria
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…
2010 Pipeline Report
HIV, Tuberculosis, and Viral Hepatitis: Drugs, diagnostics, Vaccines, Immune-based therapies, and Preventive Technologies in Development. By Polly Clayden, Lei Chou, Simon Collins, Mark Harrington, Richard Jefferys, Eleonora Jimenez, Scott Morgan, Tracy Swan, Javid Syed and Claire Wingfield.